Evidence map›Paper›PMID 41096905›Full record

ArticleInternational journal of molecular sciences2025

Interplay of the Genetic Variants and Allele Specific Methylation in the Context of a Single Human Genome Study.

Maria D Voronina, Olga V Zayakina, Kseniia A Deinichenko, Olga Sergeevna Shingalieva, Olga Y Tsimmer, Darya A Tarasova, Pavel Alekseevich Grebnev, Ekaterina A Snigir, Sergey I Mitrofanov, Vladimir S Yudin and 4 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maria D VoroninaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.
Olga V ZayakinaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.
Kseniia A DeinichenkoFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.ORCID 0009-0000-6957-4182
Olga Sergeevna ShingalievaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.
Olga Y TsimmerFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.
Darya A TarasovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.
Pavel Alekseevich GrebnevFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.ORCID 0000-0003-1077-415X
Ekaterina A SnigirFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.ORCID 0000-0003-1245-7764
Sergey I MitrofanovFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.ORCID 0000-0003-0358-0568
Vladimir S YudinFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.ORCID 0000-0002-9199-6258
Anton A KeskinovFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.
Sergey M YudinFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.ORCID 0000-0002-7942-8004
Dmitry V SvetlichnyyFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency (Centre for Strategic Planning of the Federal Medical and Biological Agency), Pogodinskaya Street, 10, bld. 1, 119121 Moscow, Russia.ORCID 0000-0002-3776-9871
Veronika I SkvortsovaThe Federal Medical Biological Agency (FMBA of Russia), Volokolamskoye Shosse, bld. 30, 123182 Moscow, Russia.

Funding

The study was conducted using internal funding from the Federal Medical-Biological Agency (FMBA) of Russia. No external funding was received.
6 · The paper itself

Abstract

The methylation of CpG sites with 5mC mark is a dynamic epigenetic modification. However, the relationship between the methylation and the surrounding genomic sequence context remains poorly explored. Investigation of the allele methylation provides an opportunity to decipher the interplay between differences in the primary DNA sequence and epigenetic variation. Here, we performed high-coverage long-read whole-genome direct DNA sequencing of one individual using Oxford Nanopore technology. We also used Illumina whole-genome sequencing of the parental genomes in order to identify allele-specific methylation sites with a trio-binning approach. We have compared the results of the haplotype-specific methylation detection and revealed that trio binning outperformed other approaches that do not take into account parental information. Also, we analysed the cis-regulatory effects of the genomic variations for influence on CpG methylation. To this end, we have used available Deep Learning models trained on the primary DNA sequence to score the cis-regulatory potential of the genomic loci. We evaluated the functional role of the allele-specific epigenetic changes with respect to gene expression using long-read Nanopore RNA sequencing. Our analysis revealed that the frequency of SNVs near allele-specific methylation positions is approximately four times higher compared to the biallelic methylation positions. In addition, we identified that allele-specific methylation sites are more conserved and enriched at the chromatin states corresponding to bivalent promoters and enhancers. Together, these findings suggest that significant impact on methylation can be encoded in the DNA sequence context. In order to elucidate the effect of the SNVs around sites of allele-specific methylation, we applied the Deep Learning model for detection of the cis-regulatory modules and estimated the impact that a genomic variant brings with respect to changes to the regulatory activity of a DNA loci. We revealed higher cis-regulatory impact variants near differentially methylated sites that we further coupled with transcriptomic long-read sequencing results. Our investigation also highlights technical aspects of allele methylation analysis and the impact of sequencing coverage on the accuracy of genomic phasing. In particular, increasing coverage above 30X does not lead to a significant improvement in allele-specific methylation discovery, and only the addition of trio binning information significantly improves phasing. We investigated genomic variation in a single human individual and coupled computational discovery of cis-regulatory modules with allele-specific methylation (ASM) profiling. In this proof-of-concept analysis, we observed that SNPs located near methylated CpG sites on the same haplotype were enriched for sequence features suggestive of high-impact regulatory potential. This finding-derived from one deeply sequenced genome-illustrates how phased genetic and epigenetic data analyses can jointly put forward a hypotheses about the involvement of regulatory protein machinery in shaping allele-specific epigenetic states. Our investigation provides a methodological framework and candidate loci for future studies of genomic imprinting and cis-mediated epigenetic regulation in humans.

Indexed as

AllelesDNA MethylationGenetic VariationGenome, HumanCpG IslandsEpigenesis, GeneticHumansPolymorphism, Single NucleotideSequence Analysis, DNAWhole Genome Sequencingallele-specific methylationcis-regulationepigenetics

Identifiers

PMID41096905
PMCPMC12525282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.